|
|
BUY XOLIAR
The drug Xoliar developed by drug manufacturer Novartis is
recommended for patients with persistent allergic asthma who
have severe problems such as reduced lung function, despite
using high dose inhaled treatments. Xoliar treatment can be
considered for patients who have been tested for IgE-mediated
asthma i.e., asthma that is allergic. The benefits of anti-IgE
therapy are already recognized within international
treatment guidelines developed by the Global Initiative for
Asthma (GINA), which recommend anti-IgE as add-on treatment
for patients with severe allergic asthma that is
inadequately controlled by standard clinical treatment
options.
BUY XOLIAR ONLINE
Studies involving 4,300 patients show that Xoliar
significantly decreases asthma attacks, almost halves
emergency visits and improves quality of life. Patients
within European clinical trials were categorized with
persistent, allergic asthma, which remained insufficiently
controlled despite the best conventional therapy, including
inhaled corticosteroids, long-acting beta2-agonists and
other controller medications. Long-term studies have
recently shown that effective control is maintained with
Xolair over a three-year period.
Buying Xoliar is much easy in U S and U K because it has
received approval from the FDA for marketing this product.
The UK has one of the highest hospital admission and
mortality rates for asthma compared to other nations. Asthma
affects more than 5.2 million people in the UK and kills
more than 1,400 people every year, whilst also leading to
69,000 annual hospital admissions. Over 50% of severe asthma
is considered allergic with symptoms and attacks caused by
environmental allergens such as dog hair, pollen and dust
mites.
|
|
